Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb hails ‘solid’ fourth-quarter performance

Bristol-Myers Squibb hails ‘solid’ fourth-quarter performance

28th January 2011

Bristol-Myers Squibb has published its fourth quarter financial report for 2010, highlighting improved sales and key clinical developments.

The company generated $5.11 billion (3.21 billion pounds) from sales during the three months, up by two percent compared to Q4 2009 and contributing to an overall annual sales total of $19.48 billion.

This growth was led by rising demand for treatments such as Plavix, Onglyza, Baraclude and Orencia, which helped to offset falling sales for certain mature brands.

During the quarter, the firm was also able to complete its acquisition of ZymoGenetics, while agreeing new partnerships with Oncolys BioPharma and Pharmasset.

Furthermore, it will be allying with the Chinese company Simcere Pharmaceutical Group to co-develop the anti-cancer agent BMS-817378.

Bristol-Myers Squibb now expects to achieve low to mid-single-digit revenue growth in 2011.

Lamberto Andreotti, chief executive officer of Bristol-Myers Squibb, said: "We anticipate several key pipeline events that will help shape our future as we continue to position our company for long-term success as a focused, differentiated biopharmaceutical company."ADNFCR-8000103-ID-800370820-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.